{"id":49467,"date":"2018-11-29T00:00:00","date_gmt":"2018-11-28T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/"},"modified":"2020-11-18T14:55:19","modified_gmt":"2020-11-18T13:55:19","slug":"iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/","title":{"rendered":"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors"},"content":{"rendered":"<p>A public-private consortium, led by biotechnology Iproteos, based at the Barcelona Science Park (Parc Cient\u00edfc de Barcelona, PCB), has launched a project to develop an innovative therapeutic strategy, designed by the Institute of Bioengineering of Catalonia (IBEC), for the treatment of tumors Solids, which account for 90% &#8211; 95% of cancer cases. The consortium also participates in the Vall d&#8217;Hebron Research Institute (VHIR).<\/p>\n<p>The ultimate goal is to validate a family of peptidomimetic compounds (new generation drugs able to cross the cell membrane) with a totally new mechanism for cancer treatment, in order to carry out preclinical regulatory trials.<\/p>\n<p>In a first phase, the consortium members will focus on rhabdomyosarcoma and neuroblastoma &#8211; two of the most common solid tumors in children and adolescents &#8211; and in lung and colon cancer, the types of cancer with higher incidence and mortality in adults, with 1,8 million and 881,000 deaths per year respectively, according to the International Agency for Research on Cancer (<a href=\"http:\/\/www.iarc.fr\/en\/media-centre\/pr\/2018\/pdfs\/pr263_E.pdf\" style=\"font-weight: 200\" target=\"_blank\" rel=\"noopener noreferrer\">IARC<\/a>) of the World Health Organization (WHO).<\/p>\n<p><span style=\"font-size:16px\"><strong>An innovative anti-tumour action mechanism<\/strong><\/span><\/p>\n<p>Researchers from IBEC\u2019s <a href=\"http:\/\/www.ibecbarcelona.eu\/cellmolmech\" style=\"font-weight: 200\" target=\"_blank\" rel=\"noopener noreferrer\">Cellular and Molecular Mechanobiology Group<\/a>, led by Pere Roca-Cusachs, discovered that the binding of proteins talin and vinculin \u2013 triggered by mechanical forces exerted by cells in response to an increase in rigidity of the surrounding tissue \u2013 triggers the activation of an important oncogen called YAP, present in most solid tumors. The results of the research \u2013 published in Nature Cell Biology in 2016 (<a href=\"https:\/\/www.nature.com\/articles\/ncb3336\" style=\"font-weight: 200\" target=\"_blank\" rel=\"noopener noreferrer\">DOI: 10.1038\/ncb3336<\/a>)\u2013 \u00a0revealed that the inhibition of the interaction of both proteins prevents activation of YAP, and has the potential to slow down, stop or even reverse tumor growth.<\/p>\n<p>\u201cInstead of focusing on genetic mutations or biochemical factors, we intend to attack tumors based on their mechanical properties, which undergo major changes,\u201d explains Pere. \u201cThis represents a completely new strategy in cancer therapy that could potentially be revolutionary, and be used in combination with other more conventional therapies.\u201d<\/p>\n<p>The biotechnology company Iproteos will address the design, synthesis and characterization of molecules that inhibit the interaction of talin and vinculin using its <a href=\"http:\/\/www.iproteos.com\/why-iprotech\" style=\"font-weight: 200\" target=\"_blank\" rel=\"noopener noreferrer\">IPROTech<\/a> platform, a state-of-the-art technology that combines computational (in silico) chemistry tools with biotechnology (in vitro) to accelerate the design of a new generation of peptide-based drugs.<\/p>\n<p>\u201cThe new mechanism discovered by Pere\u2019s group is of great relevance, given its prevalence in the majority of malignant solid tumors, the most frequent in cancer,\u201d says Teresa Tarrag\u00f3, co-founder and CEO of Iproteos. \u201cThis project has great potential, since it encompasses a broad market that calls for new innovative drugs that can help improve current survival rates. Our IPROTech platform will play a fundamental role, as it allows us to obtain drugs for complicated targets, such as protein-protein interactions.\u201d<\/p>\n<p>The <a href=\"https:\/\/www.vallhebron.com\/en\/translational-research-cancer-children-and-teenagers\" style=\"font-weight: 200\">Translational Research Group on Cancer in Children and Teenagers<\/a> at the VHIR, led by Dr. Josep S\u00e1nchez de Toledo and Dr. Soledad Gallego, will evaluate the anti-oncogenic effects of the drug candidates in pediatric tumors in vitro and in vivo, a study that will be led by Dr. Josep Roma. Obtaining results on bioavailability, pharmacokinetics and pharmacodynamics will be key to the development of the project, as well as being crucial for initiating the concept tests at the optimum dose.<\/p>\n<p>\u201cThis project opens a new promising avenue for the development of new drugs based on highly innovative biological mechanisms for the fight against cancer,\u201d says Dr. Roma. \u201cResearch to develop new drugs often focuses exclusively on adult tumors and ignores tumors in children, so that\u2019s even more added value for the project. The solid infant tumors included in this study still show a clearer survival below the average for children\u2019s cancers, and therefore, it is very necessary to study new ways of treatment in order to improve their survival rates.\u201d<\/p>\n<p>The year-long project, \u201cDevelopment of an innovative therapy for the treatment of solid tumors by means of the inhibition of the mecanotransduction\u201d, has received a grant of \u20ac 935,000 euros from the Ministry of Science, Innovation and Universities through of the call <a href=\"http:\/\/www.ciencia.gob.es\/portal\/site\/MICINN\/menuitem.791459a43fdf738d70fd325001432ea0\/?vgnextoid=b460bc05f418b510VgnVCM1000001d04140aRCRD&amp;vgnextchannel=33f85656ecfee310VgnVCM1000001d04140aRCRD&amp;vgnextfmt=formato2&amp;id3=d905964afc06e510VgnVCM1000001d04140a____\" target=\"_blank\" rel=\"noopener noreferrer\">Retos-Colaboraci\u00f3n 2017<\/a> of the \u2018Programa Estatal de I+D+i Orientada a los Retos de la Sociedad\u2019 (<a href=\"http:\/\/www.ciencia.gob.es\/stfls\/eSede\/Ficheros\/2018\/PRD_Proyectos_I_D_Retos_2017.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Exp. RTC-2017-6505-1<\/a>).<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The biotechnology company\u00a0<a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_005306&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3Diproteos%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">Iproteos<\/a>\u00a0and\u00a0the Institute of Bioengineering of Catalonia (<a href=\"http:\/\/www.pcb.ub.edu\/portal\/en\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_000134&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fen%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dibec%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">IBEC<\/a>),\u00a0based at the Barcelona Science Park (PCB), and\u00a0the Vall d&#8217;Hebron Research Institute (<a href=\"http:\/\/en.vhir.org\/portal1\/homepage.asp?\" target=\"_blank\" rel=\"noopener noreferrer\">VHIR<\/a>) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.\u00a0The project, which received \u20ac935,000\u00a0from the Ministry of Science, Innovation and Universities,\u00a0through of the call <a href=\"http:\/\/www.ciencia.gob.es\/portal\/site\/MICINN\/menuitem.791459a43fdf738d70fd325001432ea0\/?vgnextoid=b460bc05f418b510VgnVCM1000001d04140aRCRD&amp;vgnextchannel=33f85656ecfee310VgnVCM1000001d04140aRCRD&amp;vgnextfmt=formato2&amp;id3=d905964afc06e510VgnVCM1000001d04140a____\" rel=\"noopener noreferrer\" target=\"_blank\">Retos Colaboraci\u00f3n<\/a>, will focus in its first phase on two of the most common solid tumors in children and adolescents, rhabdomyosarcoma and neuroblastoma, as well as in lung and colon cancer, which have the highest mortality rate in adults.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":53042,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49467","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The biotechnology company\u00a0Iproteos\u00a0and\u00a0the Institute of Bioengineering of Catalonia (IBEC),\u00a0based at the Barcelona Science Park (PCB), and\u00a0the Vall d&#039;Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.\u00a0The project, which received \u20ac935,000\u00a0from the Ministry of Science, Innovation and Universities,\u00a0through of the call Retos Colaboraci\u00f3n, will focus in its first phase on two of the most common solid tumors in children and adolescents, rhabdomyosarcoma and neuroblastoma, as well as in lung and colon cancer, which have the highest mortality rate in adults. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-28T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-18T13:55:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/11\/16057065715fb5234b18e0c.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1218\" \/>\n\t<meta property=\"og:image:height\" content=\"508\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors\",\"datePublished\":\"2018-11-28T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/\"},\"wordCount\":690,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/16057065715fb5234b18e0c.jpeg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/\",\"name\":\"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/16057065715fb5234b18e0c.jpeg\",\"datePublished\":\"2018-11-28T23:00:00+00:00\",\"dateModified\":\"2020-11-18T13:55:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/16057065715fb5234b18e0c.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/16057065715fb5234b18e0c.jpeg\",\"width\":1218,\"height\":508},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors - Parc Cient\u00edfic de Barcelona","og_description":"The biotechnology company\u00a0Iproteos\u00a0and\u00a0the Institute of Bioengineering of Catalonia (IBEC),\u00a0based at the Barcelona Science Park (PCB), and\u00a0the Vall d'Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.\u00a0The project, which received \u20ac935,000\u00a0from the Ministry of Science, Innovation and Universities,\u00a0through of the call Retos Colaboraci\u00f3n, will focus in its first phase on two of the most common solid tumors in children and adolescents, rhabdomyosarcoma and neuroblastoma, as well as in lung and colon cancer, which have the highest mortality rate in adults. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2018-11-28T23:00:00+00:00","article_modified_time":"2020-11-18T13:55:19+00:00","og_image":[{"width":1218,"height":508,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/11\/16057065715fb5234b18e0c.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors","datePublished":"2018-11-28T23:00:00+00:00","dateModified":"2020-11-18T13:55:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/"},"wordCount":690,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/11\/16057065715fb5234b18e0c.jpeg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/","url":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/","name":"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/11\/16057065715fb5234b18e0c.jpeg","datePublished":"2018-11-28T23:00:00+00:00","dateModified":"2020-11-18T13:55:19+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/11\/16057065715fb5234b18e0c.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2018\/11\/16057065715fb5234b18e0c.jpeg","width":1218,"height":508},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/iproteos-ibec-and-vhir-to-develop-an-innovative-therapy-against-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=49467"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49467\/revisions"}],"predecessor-version":[{"id":53041,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/49467\/revisions\/53041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/53042"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=49467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=49467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=49467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}